NYSE· Real Estate Investment Trusts· Inc. MD· CIK 0001393311

PSA

Public Storage
$284.80 ▲ +0.28%
Prev close $284.00
Market cap$49.7B
ConsensusSell
12-mo target$335.33 (+17.8%)
▲ Neutral
Analyst conviction 4/10
Insider Buying Cluster (2 insiders)High Impact Filing (7/10)31 New Institutional Positions19 Institutional Exits Real Estate
Snapshot
The big-picture read on PSA right now — valuation, ownership and activity at a glance.
Market Cap
$49.7B
Cap Size
Large Cap
Analyst Consensus
Hold (36%)
Inst. Holders
50 funds
Inst. Value
$38.3B
Inst. Activity
31 buys / 19 sells
Insider Activity
$0.00 buy / $771.7K sell
Insider Net $
-$771.7K
Social Sentiment
54° Neutral
SEC Reports
15
Congressional
2 trades
Price chart 30d -5.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 18, 2026 drug_approval
EMA: Human medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion
Human medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion
Sep 14, 2026 SEC
Public Storage filed an 8-K on September 14, 2026, solely to disclose that it posted an investor presentation on its web
8-K — Impact 2/10
Sep 10, 2026 SEC
Public Storage (PSA) subsidiary PS Canada Finance ULC entered into an underwriting agreement to issue C$400 million (app
8-K — Impact 4/10
Sep 1, 2026 SEC
Public Storage completed its acquisition of PS Canada for ~$1.2B upfront (2.76M OP units at $321.98/unit + $310M cash),
8-K — Impact 7/10
Sep 1, 2026 Insider
Sheek Samuel Wade was granted 6,213 shares
Chief Legal Officer
Aug 13, 2026 Insider
Vitan Nathaniel A. sold 1,414 shares
Chief Legal Officer @ $327.53 ($463.1K)
Jul 29, 2026 Insider
HAVNER RONALD L JR acquired via exercise 34,599.51 shares
Director
Jun 30, 2026 Inst.
Capital International Investors — ADD
9,498,439 shares ($3.0B)
Analyst ratings buy % -37.9%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
Sell 36% rate it Buy or better · 25 analysts
Strong Buy 3 12% Buy 6 24% Hold 16 64% Sell 0 0% Strong Sell 0 0%
Recent analyst actions
DateFirmActionRatingFirm rating
Oct 2, 2026Truist SecuritiesMAINTAINBuy 55%
Sep 21, 2026Evercore ISI GroupMAINTAINIn-Line 59%
Sep 21, 2026JP MorganMAINTAINNeutral 55%
Sep 10, 2026BarclaysMAINTAINEqual-Weight 54%
Sep 2, 2026ScotiabankMAINTAINSector Outperform 56%
Sep 2, 2026MizuhoMAINTAINNeutral 52%
Aug 19, 2026BarclaysMAINTAINEqual-Weight 54%
Aug 18, 2026ScotiabankMAINTAINSector Outperform 56%
Jul 31, 2026RBC CapitalMAINTAINSector Perform 55%
Jul 10, 2026UBSMAINTAINNeutral 55%
Monthly consensus history
PeriodStr. BuyBuyHoldSellStr. SellBuy %Distribution
Sep 1, 202636160036%
Aug 1, 202636160036%
Jul 1, 202637130043%
Jun 1, 202637130043%
May 1, 202637130043%
Apr 1, 202637130043%
Mar 1, 202637150040%
Feb 1, 202648130048%
Price targets
Where 18 covering analysts think PSA trades over the next 12 months.
$335.33 +17.8% upside Buy
Current$284.62 Low$285.00 Median$339.50 High$374.00 18 analysts
$285.00$374.00
Analyst rating Buy· 2.5/5 as of Oct 2, 2026
Social media sentiment mood +0.0%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
54°
Neutral
BearishNeutralBullish
30 mentions 8 bullish 5 bearish 17 neutral
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
15 SEC filing reports analyzed · 3 bullish, 0 bearish, 2 mixed, 10 neutral · avg impact 4.1/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 18, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion
Human medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: Opinion
Sep 18, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Frehemgo, denecimig, Status: Opinion
Human medicines European public assessment report (EPAR): Frehemgo, denecimig, Status: Opinion
Sep 18, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Inijaq, tofacitinib, Status: Opinion
Human medicines European public assessment report (EPAR): Inijaq, tofacitinib, Status: Opinion
Sep 18, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion
Human medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: Opinion
Sep 18, 2026
drug_approval
EMA: Human medicines European public assessment report (EPAR): Sepalna, senaparib, Status: Opinion
Human medicines European public assessment report (EPAR): Sepalna, senaparib, Status: Opinion
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
PeriodEPS Est.RangeGrowth30d RevUp/DnRevenue#
Current Q$2.29$1.90–$2.69-12.3%-6.6%1↑ 0↓$1.3B4
Next Q$2.38$2.00–$2.70-8.8%-4.6%1↑ 0↓$1.4B4
Current FY$9.77$9.10–$10.32-4.5%-1.1%1↑ 0↓$5.1B4
Next FY$9.85$8.36–$11.190.8%-2.6%1↑ 0↓$5.5B5
Current-quarter EPS estimate — revision history
WhenEPS estimateChange vs now
Current$2.295—
7d ago$2.426-0.132
30d ago$2.456-0.162
60d ago$2.130+0.165
90d ago$2.201+0.094
Institutional ownership
Which big funds own PSA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $38.3B total value (120,095,689 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, VANGUARD. Net buying activity: 31 institutions added/increased vs 19 reduced.
Top holders — 2026-Q2
FundSharesValue% TrackedLast move
BlackRock, Inc.17,263,289$5.5B14.4%—
VANGUARD PORTFOLIO MANAGEMENT LLC13,608,702$4.3B11.3%—
VANGUARD CAPITAL MANAGEMENT LLC10,322,146$3.3B8.6%—
STATE STREET CORP10,133,791$3.2B8.4%—
Capital International Investors9,498,439$3.0B7.9%ADD +49.3%
NORGES BANK4,341,196$1.4B3.6%NEW
GEODE CAPITAL MANAGEMENT, LLC4,263,663$1.4B3.5%—
CHARLES SCHWAB INVESTMENT MANAGEMENT INC3,319,405$1.1B2.8%—
JPMORGAN CHASE & CO3,152,507$1.0B2.7%—
FMR LLC3,082,787$981.3M2.6%—
Recent position changes
FundActionPrevCurrentChangeValue
Capital International InvestorsADD6,363,8189,498,439+49.3%$3.0B
NORGES BANKNEW—4,341,196—$1.4B
DEUTSCHE BANK AG\ADD664,0761,259,073+89.6%$400.8M
BANK OF AMERICA CORP /DE/ADD751,8081,046,348+39.2%$333.1M
UBS Group AGADD682,342876,679+28.5%$279.1M
Russell Investments Group, Ltd.ADD504,455682,363+35.3%$217.5M
BNP PARIBAS FINANCIAL MARKETSADD274,566380,081+38.4%$121.0M
RAYMOND JAMES FINANCIAL INCADD283,502358,585+26.5%$114.1M
BARCLAYS PLCTRIM448,153249,400-44.3%$79.4M
CAISSE DE DEPOT ET PLACEMENT DU QUEBECTRIM429,554205,286-52.2%$65.3M
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
17 insiders, 50 transactions. Net -$771.7K — $0.00 bought, $771.7K sold.
DateInsiderTitleTypeSharesPriceValue
Sep 1, 2026Sheek Samuel WadeChief Legal OfficerAWARD6,213——
Aug 13, 2026Vitan Nathaniel A.Chief Legal OfficerSELL1,414$327.53$463.1K
Jul 29, 2026HAVNER RONALD L JRDirectorEXERCISE34,599.51——
Jul 29, 2026HAVNER RONALD L JRDirectorEXERCISE103,275——
Jul 28, 2026Johnson NataliaCD&TOEXERCISE3,284——
Jul 28, 2026Johnson NataliaCD&TOEXERCISE10,327——
Jun 30, 2026SPOGLI RONALD PDirectorAWARD145——
Jun 30, 2026SPOGLI RONALD PDirectorAWARD5.58$318.31$1.8K
Jun 30, 2026WILLIAMS PAUL SDirectorAWARD46$318.31$14.6K
Jun 30, 2026HAVNER RONALD L JRDirectorAWARD3.95$318.31$1.3K
Congressional trades
PSA trades disclosed by members of Congress, with disclosure delay.
2 members · 1 buys / 1 sells
DateMemberPartyChamberTypeAmountAssetDisclosed
Mar 27, 2026Alan ArmstrongRSENATEBUY$1,001 - $15,000Public StorageJul 22, 2026(117d)
Jan 12, 2026Virginia FoxxRHOUSESELL$1,001 - $15,000Public StorageFeb 9, 2026(29d)
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PSA.
Shares short
6,162,452
Settlement Sep 15, 2026
Change vs prior
+4.4%
Semi-monthly cycle
Days to cover
7.3
At avg daily volume
Of shares outstanding
≈3.5%
Estimate — not % of float
All PSA filing & press-release reports (15)